Jacobs Levy Equity Management Inc. Makes New $8.56 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Jacobs Levy Equity Management Inc. bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 454,261 shares of the company's stock, valued at approximately $8,558,000. Jacobs Levy Equity Management Inc. owned 0.98% of Pacira BioSciences at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PCRX. Sterling Capital Management LLC lifted its holdings in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after buying an additional 1,208 shares in the last quarter. Ancora Advisors LLC purchased a new position in shares of Pacira BioSciences during the fourth quarter worth approximately $26,000. Caitlin John LLC raised its stake in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the period. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Up 0.9%

NASDAQ PCRX traded up $0.25 on Monday, hitting $26.11. The stock had a trading volume of 168,637 shares, compared to its average volume of 968,214. The business's fifty day moving average price is $24.88 and its 200 day moving average price is $22.44. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -12.96 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.64.

Wall Street Analyst Weigh In

Several research analysts have commented on PCRX shares. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright upped their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Finally, Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and a consensus price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.